We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

253 hedge funds and large institutions have $3.94B invested in Arena Pharmaceuticals Inc in 2020 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 83 increasing their positions, 92 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more call options, than puts

Call options by funds: $117M | Put options by funds: $22.3M

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

16% more capital invested

Capital invested by funds: $3.4B → $3.94B (+$541M)

2% more funds holding

Funds holding: 247253 (+6)

10% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 92

11% less funds holding in top 10

Funds holding in top 10: 98 (-1)

Holders
253
Holders Change
+6
Holders Change %
+2.43%
% of All Funds
5.1%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.16%
New
36
Increased
83
Reduced
92
Closed
30
Calls
$117M
Puts
$22.3M
Net Calls
+$94.7M
Net Calls Change
+$70.6M
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
26
Eagle Asset Management
Florida
$42.4M -$14.8M -221,955 -28%
CS
27
Credit Suisse
Switzerland
$42.1M -$463K -6,940 -1%
Victory Capital Management
28
Victory Capital Management
Texas
$41.5M -$4.06M -60,871 -10%
Primecap Management
29
Primecap Management
California
$39.7M -$1.59M -23,870 -4%
Macquarie Group
30
Macquarie Group
Australia
$39.4M
Wells Fargo
31
Wells Fargo
California
$31.2M -$793K -11,889 -3%
SAM
32
Sectoral Asset Management
Quebec, Canada
$30.7M +$3.13M +47,005 +13%
CTA
33
Carillon Tower Advisers
Florida
$30.6M -$9.73M -145,987 -26%
Charles Schwab
34
Charles Schwab
California
$28.2M +$286K +4,289 +1%
CS
35
Candriam SCA
Luxembourg
$27.6M -$5.64M -84,519 -19%
BM
36
Bridger Management
New York
$27.1M -$11.6M -174,300 -32%
LCM
37
Laurion Capital Management
New York
$22.4M +$20M +300,000 New
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$21.3M -$11.9M -179,157 -39%
ACM
39
Atika Capital Management
New York
$20.6M +$4.11M +61,700 +29%
BNP Paribas Asset Management
40
BNP Paribas Asset Management
France
$20.2M +$484K +7,261 +3%
FLAM
41
First Light Asset Management
Minnesota
$19.8M +$16.6K +249 +0.1%
EMG
42
ETF Managers Group
New Jersey
$19.3M -$3.49M -52,314 -17%
RCAMU
43
Rothschild & Co Asset Management US
Connecticut
$18.5M -$2.46M -36,891 -13%
GLA
44
Great Lakes Advisors
Illinois
$18.3M +$10.3M +153,989 +171%
Handelsbanken Fonder
45
Handelsbanken Fonder
Sweden
$17.5M +$1.33M +20,000 +9%
RPAM
46
Rhenman & Partners Asset Management
Sweden
$15.8M
Deutsche Bank
47
Deutsche Bank
Germany
$14.7M -$438K -6,571 -3%
Axa
48
Axa
France
$14.5M -$3.19M -47,858 -20%
Ameriprise
49
Ameriprise
Minnesota
$14.5M +$3.24M +48,594 +34%
Two Sigma Investments
50
Two Sigma Investments
New York
$14.1M +$10.1M +151,224 +401%

ARNA Hedge Fund Activity: Q3 2020 in Review

253 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q3 2020, worth a combined $3.94B — up 16% from $3.4B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ARNA positions and 30 closed out — a net gain of 6 holders — while 83 added to existing stakes and 92 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $143M. The largest seller was Citadel Advisors, cutting an estimated $59.8M.

  • 253 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q3 2020, up from 247 in Q2 2020.
  • Funds reported $3.94B of Arena Pharmaceuticals Inc stock for Q3 2020, up 16% quarter-over-quarter.
  • 36 funds opened new Arena Pharmaceuticals Inc positions in Q3 2020 and 30 closed out, a net change of +6 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q3 2020 was Avoro Capital Advisors, an estimated $143M added.
  • The largest Arena Pharmaceuticals Inc seller in Q3 2020 was Citadel Advisors, an estimated $59.8M sold.

Based on aggregated 13F filings for Q3 2020.